RxDoctor Payments Data

Alison Granier, MD

Ophthalmology · Coeur D Alene, IDNPI 1669709143

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $2,826 of the $4,463 with a category attached, or 63.3%. Glaukos Corporation accounts for 68.8% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2023 at $2,849 and has fallen 93.0% since, to $199 in 2025. Among ophthalmology clinicians in ID with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$4,463in general payments, 2019–2025

Across 53 payments — averaging $84.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Glaukos Corporation$3K
  • Alcon$343
  • Regeneron Healthcare Solutions, Inc.$306
  • Astellas Pharma US Inc$148
  • Ivantis, Inc$147
  • Genentech USA, Inc.$114
  • plus $333 from 12 others

What the payments were for

  • Travel & lodging$2,82663%
  • Food & beverage$1,63737%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,463 in reported general payments places this provider in the 90th percentile of 60 ophthalmology providers in Idaho.

See all ophthalmology providers in Idaho

Medicare billing

Part B allowed, 2024
$1,266,487
Medicare patients
1,112
Services billed
9,492

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine17$27,468
RocklatanNetarsudil Mesylat/Latanoprost36$16,624
Cyclosporine14$9,740
Latanoprost389$5,691
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol15$3,354
Alphagan PBrimonidine Tartrate15$3,192
Brinzolamide21$2,541
Bromfenac Sodium19$2,020
Prednisolone Acetate48$1,846
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat113$1,836
Timolol Maleate171$1,369
Doxycycline Monohydrate45$1,269
Eplerenone13$1,132
Fluorometholone16$1,121
Brimonidine Tartrate101$684

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Aerie Pharmaceuticals, Inc.Rocklatan$45$16,62436 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 60 ophthalmology providers in Idaho.

Other ophthalmology in Coeur D Alene

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →